Before a sponsor assumes a changed drug product needs the full weight of a 505(b)(2) application, 21 CFR 314.93 offers a narrower door: ask FDA's permission to file an ANDA anyway. The request is a suitability petition, and FDA will deny it the moment the proposed change actually requires studies to establish safety or effectiveness — which is exactly what most meaningful product differences do. The petition is not a formality. It is the test that decides which pathway, and which clock, applies.

The fork before you file anything

A suitability petition exists for one narrow purpose: to ask FDA, before an ANDA is ever submitted, whether a product that differs from an approved reference listed drug can still be filed as an abbreviated application. The eligible differences are limited — route of administration, dosage form, strength, or, for a fixed-combination product, one active ingredient. FDA must act on the petition first; the ANDA cannot be submitted until the petition is approved. Get this sequencing wrong and the ANDA itself is dead on arrival, independent of its scientific content.

90 days
The statutory target for FDA to approve or deny a suitability petition under 314.93(e).
FY2024+
Petitions submitted from this point get a GDUFA III goal date; earlier pending petitions do not unless refiled.
50% → 90%
FDA's committed share of petitions reviewed within six months of the completeness check, rising from FY2024 to FY2027.

Why FDA denies most of them

Section 314.93(e) sets the standard: FDA approves the petition unless it finds a specific reason not to. The two grounds that do most of the work are straightforward in theory and brutal in practice. First, if establishing the safety or effectiveness of the proposed difference — a new route, a new strength, a changed dosage form — would require investigations, the petition is denied, because that is precisely the bar a pharmaceutical regulatory strategy built around abbreviated review is designed to avoid crossing. Second, if the change would require significant labeling updates to address a newly identified safety or effectiveness problem, the same result follows. Most product differences that are commercially worth pursuing are differences precisely because they change how the drug behaves — which is the same reason they tend to need the studies that sink the petition.

  1. A stand-alone NDA. Full safety and effectiveness data, for a product with no eligible reliance on a reference listed drug.
  2. A 505(b)(2) application. Relies in part on FDA's finding of safety or effectiveness for a listed drug, plus the sponsor's own bridging data.
  3. An ANDA for a duplicate. A product that duplicates an RLD and is eligible under 505(j) — and generally cannot be filed as a 505(b)(2) instead, which is its own refuse-to-file exposure.
  4. A petitioned ANDA. An ANDA for a product that differs from the RLD in a 314.93-eligible way, filed only after FDA approves the suitability petition.
The petition is not a way around the 505(b)(2) pathway. It is the test for whether you were ever required to take it — and FDA built the denial standard so that most real product changes fail it. Why the suitability petition decides the pathway, not the other way around

The 2026 draft narrows one edge case further

FDA's guidance on choosing between an ANDA and a 505(b)(2) application was finalized in May 2019 and, as of a draft Revision 1 issued in August 2026, FDA has proposed updating it — still a draft, not yet binding, so treat the detail as directional rather than settled. The expansion focuses on a scenario the 2019 version addressed only thinly: a reference listed drug that has been discontinued, where a sponsor cannot run the head-to-head bioequivalence study an ANDA would normally require. The draft's direction is to route that situation to FDA's Office of Generic Drugs for alternate bioequivalence approaches first, reserving 505(b)(2) for cases where no acceptable ANDA alternative exists at all — reinforcing, from a different angle, the same point the suitability petition makes: 505(b)(2) is where you end up when the abbreviated routes have genuinely run out, not a default.

A suitability-petition readiness sequence
  1. Map the change against the four eligible categories. Route, dosage form, strength, or one active ingredient in a combination — nothing broader qualifies.
  2. Test the studies-necessary question honestly. If establishing safety or effectiveness of the difference needs data you don't already have, expect a denial.
  3. Confirm the RLD is still active. A discontinued reference drug changes the analysis before you ever reach the petition.
  4. Plan around the real goal-date math. Use FDA's current GDUFA III review-rate commitments, not the 90-day statutory figure, to set expectations.

The same logic runs in both directions. A sponsor who files a 505(b)(2) for a product that is simply a duplicate of an approved RLD and eligible for ANDA review faces the drug-side analogue of a device sponsor's completeness problem — FDA's refuse-to-file authority exists for NDAs and BLAs for exactly this kind of threshold failure, before substantive review ever starts. Getting the pathway choice right at the suitability-petition stage is cheaper than finding out which gate you missed sixty days after submission.

Frequently asked questions

What is an FDA suitability petition?

A request under 21 CFR 314.93 asking FDA's permission to file an ANDA for a drug product that differs from its reference listed drug in route of administration, dosage form, strength, or — in a fixed-combination product — one active ingredient. FDA must approve the petition before the ANDA itself can be submitted.

Why would FDA deny a suitability petition?

Under 314.93(e), FDA approves a petition unless it finds a reason not to — most commonly that investigations are necessary to establish the safety or effectiveness of the proposed difference, or that the change would require significant labeling updates to address a newly identified safety or effectiveness concern. Most meaningful product changes trigger one of those grounds.

How long does FDA take to decide a suitability petition?

The statutory target is 90 days, but actual response times have often run far longer. Under GDUFA III, petitions submitted from fiscal year 2024 onward get an assigned goal date, with FDA's commitment letter targeting review of a rising share — 50% in FY2024 up to 90% in FY2027 — within six months of the completeness check.

Sources & further reading

  1. FDA. Determining Whether to Submit an ANDA or a 505(b)(2) Application — Draft Guidance, Revision 1 (Aug. 2026). fda.gov
  2. 21 CFR 314.93 — Petition to request a change from a listed drug. ecfr.gov

This article is provided for general informational purposes and reflects the regulatory landscape as of October 2026. It is not legal or regulatory advice. FDA's August 2026 draft guidance revision was not yet final as of publication; confirm current suitability-petition and ANDA/505(b)(2) requirements with FDA or qualified counsel before acting.